CH50 Activity and its Relationship to Antimüllerian Hormone in Patients with Infertility| Stephy Publishers

 

Current Investigations in Clinical and Medical Research - (CICMR)| Stephy Publishers

Abstract

Objective: To study the importance of immunological screening (CH50, C3, C4) to determine the correlation between the ovarian reserve and complement pathway.

 
Design: A cross-sectional multivariate study.

 
Setting: Single tertiary referral center.

Patients: 40 Women with infertility diagnosis who underwent In Vitro Fertilization (IVF).

Intervention(s): Basal blood samples collected to measure complement pathway and antimüllerian hormone.
Main Outcome Measure(s): To correlate complement pathways (CH50 levels) with AMH. Results: The complement system and ovarian reserve were studied in 40 women aged from 28-48 years (mean=37.87 years), finding the values of CH50 65-268 CAE (mean=153.2 CAE), C3 13.9- 183mg/dl (mean=128.52mg/dl), C4 11.5-106mg/dl (mean=29.86mg/dl), AMH 0.10-3.9ng/dl (mean=1.32ng/dl). A multivariate analysis comparison was also conducted yielding significant.

Results: negative correlation between AMH and age (Spearman correlation -0.6; P=0.001), as well as between AMH and CH50 (Spearman correlation -0.4; P=0.0129).

Conclusion: High CH50 levels are correlated with an AMH decrease and it could be accordingly associated with age-related chronic inflammation. Capsule: High levels of CH50 are correlated with a decrease in AMH levels and could also be considered as a marker of poor response in IVF cycles.

Keywords: CH50, AMH, Immune infertility, Complement pathways, ovarian reserve

Introduction
In modern age, behavior and lifestyle have changed dramatically due to modifications in fertility factors. Advanced maternal age, inflammatory alterations, and concomitant diseases can change fertility rate over time. We can use the ovarian reserve as a fertility predictor since it is a concept that reflects the quality and quantity of oocytes present in the ovary.1,2 In addition to measuring AMH to quantify the ovarian reserve other basal serum markers can be taken into account: inhibition B, follicle-stimulating hormone (FSH), and estradiol, as well as ultrasonographic markers such as ovarian volume measurement or antral follicle count (AFC).1 AMH is a dimeric glycoprotein, discovered in the 1940s, that participates in sexual differentiation, and was found in human follicles in 1990. It is produced by developing follicle granulosa cells and with clear clinical significance in ovarian function and reserve.2 Clinical applications of AMH serum measurement include menopause prediction in different patient groups, for example

In modern age, behavior and lifestyle have changed dramatically due to modifications in fertility factors. Advanced maternal age, inflammatory alterations, and concomitant diseases can change fertility rate over time. We can use the ovarian reserve as a fertility predictor since it is a concept that reflects the quality and quantity of oocytes present in the ovary.1,2 In addition to measuring AMH to quantify the ovarian reserve other basal serum markers can be taken into account: inhibition B, follicle-stimulating hormone (FSH), and estradiol, as well as ultrasonographic markers such as ovarian volume measurement or antral follicle count (AFC).1 AMH is a dimeric glycoprotein, discovered in the 1940s, that participates in sexual differentiation, and was found in human follicles in 1990. It is produced by developing follicle granulosa cells and with clear clinical significance in ovarian function and reserve.2 Clinical applications of AMH serum measurement include menopause prediction in different patient groups, for example


To read more #MedicalResearch
https://www.stephypublishers.com/cicmr/fulltext/CICMR.MS.ID.000513.php

For more #Openaccessjournals
https://www.stephypublishers.com/